Our previous study showed that the expression of miR-543-3p was obviously increased in astrocytes treated with MPP+, which could straightly regulate the function of glutamate transporter-1 (GLT-1), suggesting that an miR-543-3p inhibitor may be a new therapeutic drug for PD (Wu et al., 2019). This evidence concerns the gene SLC1A2 and Parkinson disease.